Literature DB >> 25790105

Inherited variation at MC1R and histological characteristics of primary melanoma.

Nicholas J Taylor1, Klaus J Busam2, Lynn From3, Pamela A Groben4, Hoda Anton-Culver5, Anne E Cust6, Colin B Begg7, Terence Dwyer8, Richard P Gallagher9, Stephen B Gruber10, Irene Orlow7, Stefano Rosso11, Nancy E Thomas12, Roberto Zanetti11, Timothy R Rebbeck13, Marianne Berwick14, Peter A Kanetsky1.   

Abstract

Variation in the melanocortin-1receptor (MC1R) gene is associated with pigmentary phenotypes and risk of malignant melanoma. Few studies have reported on MC1R variation with respect to tumor characteristics, especially clinically important prognostic features. We examined associations between MC1R variants and histopathological melanoma characteristics. Study participants were enrolled from nine geographic regions in Australia, Canada, Italy and the United States and were genotyped for MC1R variants classified as high-risk [R] (D84E, R142H, R151C, R160W, and D294H, all nonsense and insertion/deletion) or low-risk [r] (all other nonsynonymous) variants. Tissue was available for 2,160 white participants of the Genes, Environment and Melanoma (GEM) Study with a first incident primary melanoma diagnosis, and underwent centralized pathologic review. No statistically significant associations were observed between MC1R variants and AJCC established prognostic tumor characteristics: Breslow thickness, presence of mitoses or presence of ulceration. However, MC1R was significantly associated with anatomic site of melanoma (p = 0.002) and a positive association was observed between carriage of more than one [R] variant and melanomas arising on the arms (OR = 2.39; 95% CI: 1.40, 4.09). We also observed statistically significant differences between sun-sensitive and sun-resistant individuals with respect to associations between MC1R genotype and AJCC prognostic tumor characteristics. Our results suggest inherited variation in MC1R may play an influential role in anatomic site presentation of melanomas and may differ with respect to skin pigmentation phenotype.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25790105      PMCID: PMC4366050          DOI: 10.1371/journal.pone.0119920

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Inherited variation in the melanocortin-1 receptor (MC1R) gene is a robust genetic marker for moderately increased risk of melanoma [1]. We hypothesize that variation in MC1R influences the occurrence of melanomas that can be distinguished by histology or other tumor characteristics. However, evidence supporting a consistent association between MC1R variation and melanoma tumor characteristics is limited. Direct cross-study comparisons are hindered due in part to a lack of standardized measures and characterization of MC1R risk variants [2], coupled with differences in categorization of melanoma characteristics (e.g. collapsing of anatomic site presentation). To more thoroughly address whether MC1R variants are associated with tumor characteristics, we present results from individuals diagnosed with a first incident primary tumor in a large population-based case-control study of melanoma: the Genes, Environment and Melanoma (GEM) Study. We examined associations between variation in MC1R and American Joint Committee on Cancer (AJCC) established tumor characteristics that are associated with prognosis: Breslow thickness and presence of mitoses and ulceration [3-8], as well as with presence of tumor infiltrating lymphocytes (TILs), a purported prognostic factor [9]. We also evaluated other histopathological tumor features for associations with MC1R variation in an effort to further characterize potential etiologic heterogeneity.

Materials and Methods

GEM Study

The GEM Study is a population-based case-control study that enrolled a large series of individuals diagnosed with a first incident invasive primary cutaneous melanoma. Study participants were identified from eight population-based cancer registries and one hospital center in Australia, Canada, Italy and the United States. Detailed study recruitment methods have been previously described [10,11]. The human research oversight committees at each of the GEM study sites, including those at the British Columbia Cancer Agency, Vancouver, BC, CA; Cancer Care Ontario, Toronto, ON, CA; Centro per la Prevenzione Oncologia, Torino, IT; Memorial Sloan Kettering Cancer Center, New York, NY, US; Menzies Cancer Center, Hobart, TAS, AU; University of California, Irvine, CA, US; University of Michigan, Ann Arbor, MI, US; University of North Carolina, Chapel Hill, NC, US; and University of Sydney, Sydney, NSW, AU, approved the study protocol. Written and signed informed consent was obtained from all participants. Diagnostic pathology reports were obtained for each participant with a first incident primary melanoma (n = 2,424) from the appropriate ascertainment center, and data corresponding to histological subtype, lesion thickness, and anatomic location of lesion were abstracted. Tumor tissue slides for 2,105 (86.8%) participants with a diagnosis of first incident melanoma were available for centralized pathological review, performed in large part by one of three study pathologists (KB, LF, PG). Standardized pathologic review of slides included evaluation of: histologic subtype, Breslow thickness, Clark level, mitoses, solar elastosis, TILs, presence of satellite lesions, presence of coexisting nevi, presence of pigmentation, evidence of lesion regression, ulceration, and vertical growth phase. Melanomas were classified according to established histopathological criteria [12,13]. Since Breslow thickness was both abstracted from the pathology report and recorded during the centralized pathologic review, the measure corresponding to the deepest reading was chosen to represent the value of most biological relevance. Using a glossy colored guide to aid in differentiating between nevi and other skin lesions, participants were asked to have the nevi on their backs counted by a family member or friend; logistic models were adjusted for this continuous variable. A phenotypic index was derived using data collected from a study participant self-administered questionnaire [14], and was based on: hair color (black or dark brown = 1; light brown or blond = 2; red = 3), eye color (black or brown = 0; all other colors = 1), and relative inability to tan in response to sun exposure (no = 0; yes = 1) [15]. Phenotypic index scores of 1 and 2 indicate relatively darker cutaneous phenotypes and lower phenotypic melanoma risk; an index score of 3 indicates medium phenotypic risk. Hereinafter, we refer to individuals with any of these three scores as having a “sun-resistant” phenotype. Phenotypic index scores of 4 and 5 indicate relatively fairer cutaneous phenotypes and higher phenotypic risks for melanoma, hereinafter referred to as “sun sensitive”.

MC1R Genotyping

Details of MC1R genotyping methods, distribution of observed MC1R variants, and variant carrier status among GEM Study participants have been described previously [15,16]. We adopted nomenclature and definitions based on previous literature [1,17-20] to classify MC1R variants as conferring higher risk for melanoma based on strong association with red hair phenotype [R] (D84E, R142H, R151C, R160W, and D294H, all nonsense and insertion/deletion) or lower risk for melanoma based on weaker association with red hair phenotype [r] (all other nonsynonymous variants). Since the exact functional status of many MC1R variants is still unknown, we acknowledge that these risk categories may be inaccurate. We categorized MC1R carriage into four groups: consensus (absence of any variants), only [r] (carriage of any [r] variant in the absence of a [R] variant), one [R] (carriage of a single [R] variant), and >1 [R] (carriage of more than 1 [R] variant). Secondarily, we examined associations between MC1R variant carriage number and tumor characteristics by coding MC1R genotype based on total number of variants ([r] and [R]; 0 variants vs. 1 variant vs. 2 or more variants).

Statistical Analysis

For this report, we include only those GEM participants with first incident primary melanomas who were successfully genotyped for MC1R and who self-reported their race as white (n = 2,160). We used SAS (SAS Institute, Cary, NC) to perform multinomial logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between MC1R variant status and tumor characteristics while adjusting for sex, age at most recent melanoma diagnosis, study ascertainment center, phenotypic index and number of nevi on the back. For tumor characteristics that were modeled dichotomously, results are equivalent to those obtained from a binomial logistic regression model. We also conducted analyses stratified by sun-resistant and sun-sensitive phenotypes; we then evaluated the Wald p-value of the interaction term for sun sensitivity by MC1R to assess heterogeneity of effect between sun-sensitive and sun-resistant phenotypes. All statistical tests were two-sided with an alpha level of 0.05.

Results

Overall, tumor characteristics were not associated with genotyping success (data not shown). In univariate analyses, we compared the distributions of MC1R genotype risk categories across strata of prognostic tumor characteristics including: Breslow thickness and presence of mitoses, ulceration, or TILs. No statistically significant associations were noted among these tumor characteristics. We did observe a statistically significant association between anatomical site and MC1R variant carriage based on low-[r] and high-[R] risk variant carriage (p = 0.002) (Table 1). Our findings with respect to MC1R variant carriage number were consistent with no association (data not tabulated).
Table 1

Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between MC1R variants and histopathological tumor characteristics among first incident cases of invasive melanoma in the GEM Study.

ConsensusOnly r 1 One R 2 >1 R 2 Only r 1 vs. consensusOne R 2 vs. consensus>1 R 2 vs. consensus
Tumor characteristicn%* n%* n%* n%* OR 3 95% CIOR 3 95% CIOR 3 95% CI
Breslow thickness (mm)
0.01–1.00251184643356240136101.001.001.00
1.01–2.006014141331814342101.210.85–1.721.340.95–1.901.380.83–2.28
>2.004917103331073732111.120.75–1.650.940.63–1.391.020.58–1.79
p = 0.45
Mitoses
Absent17317315324084196101.001.001.00
Present12016260352933981111.060.79–1.431.010.76–1.361.160.76–1.78
p = 0.56
Ulceration
Absent267175263363640158101.001.001.00
Present26174731614018120.810.48–1.370.990.59–1.641.380.67–2.85
p = 0.85
Tumor infiltrating lymphocytes
Absent5915126331564143111.001.001.00
Non-brisk197183673343939112100.890.61–1.300.930.64–1.341.090.63–1.87
Brisk34157934100432191.070.63–1.821.090.65–1.840.930.43–2.02
p = 0.81
Anatomic location
Trunk or pelvis1581732334402427381.001.001.00
Head or neck591812336131392571.110.75–1.630.850.58–1.250.890.48–1.65
Arms5514137341573956141.300.88–1.921.130.77–1.662.391.40–4.09
Legs9320138301743856120.850.60–1.220.800.56–1.131.420.84–2.41
p = 0.002
Clark level
II12017234332944173101.001.001.00
III9420154321823848100.790.56–1.120.740.53–1.050.720.43–1.21
IV & V7915185342224156101.280.88–1.861.360.94–1.961.360.80–2.30
p = 0.59
Coexisting nevus
None identified231184423352440125101.001.001.00
Common acquired281277321024237151.330.83–2.141.380.86–2.191.610.87–2.97
Dysplastic3517673289431780.870.54–1.380.980.62–1.540.960.48–1.93
Congenital82411331133390.810.30–2.200.830.30–2.260.650.14–2.99
p = 0.16
Histological type
Superficial spreading267184723257740146101.001.001.00
Nodular21126737744021121.610.98–2.741.450.85–2.451.580.77–3.26
Lentigo maligna3417663380401891.160.72–1.881.110.69–1.780.910.44–1.89
Not otherwise specified40159836112421971.410.91–2.191.250.81–1.940.890.45–1.78
p = 0.28
Pigmentation
Present280175453366540161101.001.001.00
Absent22145333674121131.230.71–2.151.170.68–2.021.370.66–2.86
p = 0.54
Regression
Absent201164103348840130111.001.001.00
Present1011719033241415291.100.79–1.541.190.86–1.650.950.58–1.56
p = 0.73
Satellite
Absent199183743343739113101.001.001.00
Present186503252172.300.26–20.150.770.07–8.801.360.07–26.83
p = 0.57
Solar elastosis
Absent10517206332634260101.001.001.00
Present194173783345340119101.080.76–1.521.020.73–1.431.300.79–2.14
p = 0.79
Vertical growth phase
Absent10617207332494060101.001.001.00
Present185173643345040117111.030.75–1.411.070.79–1.461.150.73–1.83
p = 0.77

* Row percentages are presented

† Potential prognostic factor based on Thomas et al., J Clin Oncology, 2013. Vol. 33, Num. 33: 4252–59

1 r indicates carriage of V60L, V92M, I115T, R163Q, or rare nonsynonymous variants in the absence of a R variant.

2 R indicates carriage of D84E, R142H, R151C, R160W, D294H, nonsense or insertion/deletion variants.

3 ORs are adjusted for center, sex, age at melanoma diagnosis, phenotypic index, and total body mole density

* Row percentages are presented † Potential prognostic factor based on Thomas et al., J Clin Oncology, 2013. Vol. 33, Num. 33: 4252–59 1 r indicates carriage of V60L, V92M, I115T, R163Q, or rare nonsynonymous variants in the absence of a R variant. 2 R indicates carriage of D84E, R142H, R151C, R160W, D294H, nonsense or insertion/deletion variants. 3 ORs are adjusted for center, sex, age at melanoma diagnosis, phenotypic index, and total body mole density Multivariate analyses are also presented in Table 1. No statistically significant associations were noted among prognostic tumor characteristics. However, our adjusted analyses revealed a strong association between carriage of more than one MC1R [R] variant and melanoma development on the arms (OR = 2.39; 95% CI: 1.40, 4.09) when compared to individuals who developed melanomas on the trunk or pelvis. Associations between MC1R variants and strata of other melanoma tumor characteristics were consistent with no association after adjustment. Because previous reports have indicated that melanoma risk associated with carriage of high-risk [R] MC1R variants is particularly informative among individuals with darker phenotypic characteristics [21], we explored associations between MC1R variants and the four prognostic tumor characteristics by skin pigmentation phenotype. We noted statistical heterogeneity between individuals with sun-sensitive and sun-resistant phenotypes for the associations between MC1R variants and Breslow thickness (p = 0.03), presence of mitoses (p = 0.03), presence of ulceration (p = 0.04), as well as presence of TILs (p = 0.01) (Table 2). We observed relatively stronger associations between Breslow thickness and MC1R among sun-sensitive individuals. Similarly, we noted pronounced positive associations between carriage of only [r] variants (vs. carriage of only consensus) and presence of mitoses and ulceration among sun-sensitive individuals, whereas carriage of only [r] variants among sun-resistant participants showed little or no association with presence of mitoses and an inverse association with presence of ulceration. We found carriage of [R] variants was more prevalent among sun-sensitive individuals with non-brisk TILs observed in their melanomas compared to sun-resistant individuals with non-brisk TILs. In contrast, both [r] and [R] variants were more prevalent among sun-resistant cases with brisk TILs observed in their lesions compared to sun-sensitive cases with brisk TILs.
Table 2

Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between MC1R variants and prognostic histopathological tumor characteristics among first incident cases of invasive melanoma in the GEM Study, stratified by phenotype.

Phenotypically sun-sensitive** Phenotypically sun-resistant Phet
Tumor characteristicConsensusOnly r 1 Any R 2 Only r 1 vs. consensusAny R 2 vs. consensusConsensusOnly r 1 Any R 2 Only r 1 vs. consensusAny R 2 vs. consensus
n%* n%* n%* OR 3 95% CIOR 3 95% CIn%* n%* n%* OR 3 95% CIOR 3 95% CI
Breslow thickness (mm)
0.01–1.0048128721273671.001.001992135838391411.001.000.02
1.01–2.0076262188732.050.76–5.532.380.96–5.92511810938126441.100.75–1.601.180.81–1.73
>2.001211373557541.610.74–3.500.730.35–1.523520613675440.970.97–1.541.130.72–1.78
p = 0.01p = 0.92
Mitoses
Absent36125920199681.001.001332025138277421.001.000.03
Present2086929151632.031.03–4.001.310.70–2.43982017737207430.910.65–1.261.050.76–1.46
p = 0.16p = 0.99
Ulceration
Absent541111523323661.001.002082039738430421.001.000.04
Present25133226633.170.67–15.031.890.42–8.512323292850490.600.33–1.080.980.57–1.67
p = 0.64p = 0.41
Tumor infiltrating lymphocytes
Absent1311353075651.001.0044188535113471.001.000.01
Non-brisk3197221233690.810.36–1.841.530.72–3.241622228538300400.950.62–1.450.780.51–1.18
Brisk1215212647590.630.23–1.740.770.30–1.972215553866461.340.71–2.531.270.69–2.34
p = 0.30p = 0.43

* Row percentages are presented

** Based on phenotypic index greater than 2

† Based on phenotypic index less than or equal to 2

‡ Potential prognostic factor based on Thomas et al., J Clin Oncology, 2013. Vol. 33, Num. 33: 4252–59

1 r indicates carriage of V60L, V92M, I115T, R163Q, or rare nonsynonymous variants in the absence of a R variant.

2 R indicates carriage of D84E, R142H, R151C, R160W, D294H, nonsense or insertion/deletion variants.

3 ORs are adjusted for center, sex, age at melanoma diagnosis, and total body mole density

* Row percentages are presented ** Based on phenotypic index greater than 2 † Based on phenotypic index less than or equal to 2 ‡ Potential prognostic factor based on Thomas et al., J Clin Oncology, 2013. Vol. 33, Num. 33: 4252–59 1 r indicates carriage of V60L, V92M, I115T, R163Q, or rare nonsynonymous variants in the absence of a R variant. 2 R indicates carriage of D84E, R142H, R151C, R160W, D294H, nonsense or insertion/deletion variants. 3 ORs are adjusted for center, sex, age at melanoma diagnosis, and total body mole density

Discussion

The GEM Study provides well-annotated histopathological data for melanomas and complete sequencing of participant DNA at the MC1R locus, which allows for a comprehensive examination of the associations between variants and histopathological tumor characteristics. In this study we report no pronounced or statistically significant main effect associations of MC1R with AJCC accepted prognostic factors of Breslow thickness, presence of ulceration, or presence of mitoses overall. Similarly, we did not observe an association between variation in MC1R and TILs, which were shown to be an important independent prognostic feature of melanoma in GEM [9]. However, we did find a persistent positive association between carriage of more than one [R] variant and melanoma presentation on the arms after adjustment. After stratification by skin pigmentation phenotype, this observed association was limited to individuals with sun-resistant phenotypes. There are several previous reports of MC1R variation in association with anatomical site of melanoma, but they generally grouped sites together on the basis of sun-exposure before analyses and/or categorized MC1R variants differently, [22-26] and are not directly comparable to this study. We did attempt to draw a comparison between our results and results from a case-control study of sporadic and familial melanoma in a Swedish population [25], which reported an increased association between carriage of ≥1 MC1R variant and melanoma presentation on the trunk (OR = 1.54; 95% CI: 1.01, 2.37). After recapitulating their coding for anatomic site, MC1R, and other covariates to the best of our ability, we were unable to replicate that finding (data not shown). Recently, Peña-Vilabelda et. al. reported results similar to our own with respect to high-risk MC1R variants in association with melanoma tumor site presentation (Arms: OR = 2.34; 95% CI: 0.98, 5.61) [27]. Interestingly, prior studies have noted more favorable prognoses among melanomas presenting on the extremities [28,29]. Future studies of variation in MC1R related to anatomical melanoma presentation are necessary to validate our findings. We explored effect modification by phenotypic index only among the prognostic measures of Breslow thickness, ulceration, mitoses, and TILs to limit the potential for false discovery. We observed significant differences between phenotypically sun-resistant and sun-sensitive individuals with respect to all four prognostic tumor factors. Interestingly, sun-sensitive cases demonstrated stronger associations across Breslow thickness, mitoses and ulceration compared to those observed among sun-resistant individuals. These results are thought-provoking considering that it is among individuals with more sun-resistant phenotypes that MC1R has been associated with increased risk for melanoma [21,30]. However, we did note generally stronger associations between brisk TILs and MC1R among individuals with a sun-resistant phenotype compared to sun-sensitive cases. Although associations between MC1R variant carriage and all four prognostic variables were significantly different between phenotypic classifications, we were likely underpowered to detect associations within strata of phenotypic index despite the large sample size available in the GEM Study. This investigation of tumor characteristics among 2,160 first incident cases of melanoma is the largest such study to examine associations with germline variation in MC1R. A strength of this study is the population-based nature of the parent GEM Study, from which a large number of incident cases were drawn from nine international ascertainment centers, improving generalizability of results to persons of European ancestry living in a variety of climates. Other advantages of this investigation were the centralized histopathological review conducted by expert pathologists and the ability to adjust for the potential impact of skin pigment and number of nevi. However, we do acknowledge the possibility that false positive findings may have arisen due to multiple hypothesis testing and the exploratory nature of associations examined between MC1R variation and tumor factors stratified by phenotypic index; thus, these findings should be validated in larger study populations before more meaningful interpretations can be made.
  30 in total

1.  Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Authors:  Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

2.  Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.

Authors:  Manuela F Azzola; Helen M Shaw; John F Thompson; Seng-Jaw Soong; Richard A Scolyer; Geoffrey F Watson; Marjorie H Colman; Yuting Zhang
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

3.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Authors:  W H Clark; L From; E A Bernardino; M C Mihm
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

4.  Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color.

Authors:  C Kennedy; J ter Huurne; M Berkhout; N Gruis; M Bastiaens; W Bergman; R Willemze; J N Bavinck
Journal:  J Invest Dermatol       Date:  2001-08       Impact factor: 8.551

5.  Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation.

Authors:  N Flanagan; E Healy; A Ray; S Philips; C Todd; I J Jackson; M A Birch-Machin; J L Rees
Journal:  Hum Mol Genet       Date:  2000-10-12       Impact factor: 6.150

6.  Clinical characteristics of patients with cutaneous melanoma according to variants in the melanocortin 1 receptor gene.

Authors:  M M Peña-Vilabelda; Z García-Casado; C Requena; V Traves; J A López-Guerrero; C Guillén; R Kumar; E Nagore
Journal:  Actas Dermosifiliogr       Date:  2013-11-12

Review 7.  Prognostic factors in patients with localized primary cutaneous melanoma.

Authors:  Liljana Mervic
Journal:  Acta Dermatovenerol Alp Pannonica Adriat       Date:  2012

Review 8.  The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes.

Authors:  Richard A Sturm; David L Duffy; Neil F Box; Wei Chen; Darren J Smit; Darren L Brown; Jennifer L Stow; J Helen Leonard; Nicholas G Martin
Journal:  Pigment Cell Res       Date:  2003-06

9.  Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach.

Authors:  Peter A Kanetsky; Fan Ge; Derek Najarian; Jennifer Swoyer; Saarene Panossian; Lynn Schuchter; Robin Holmes; DuPont Guerry; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-05       Impact factor: 4.254

10.  MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project.

Authors:  Elena Pasquali; José C García-Borrón; Maria Concetta Fargnoli; Sara Gandini; Patrick Maisonneuve; Vincenzo Bagnardi; Claudia Specchia; Fan Liu; Manfred Kayser; Tamar Nijsten; Eduardo Nagore; Rajiv Kumar; Johan Hansson; Peter A Kanetsky; Paola Ghiorzo; Tadeusz Debniak; Wojciech Branicki; Nelleke A Gruis; Jiali Han; Terry Dwyer; Leigh Blizzard; Maria Teresa Landi; Giuseppe Palmieri; Gloria Ribas; Alexander Stratigos; M Laurin Council; Philippe Autier; Julian Little; Julia Newton-Bishop; Francesco Sera; Sara Raimondi
Journal:  Int J Cancer       Date:  2014-06-18       Impact factor: 7.396

View more
  13 in total

1.  Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.

Authors:  Cristina Pellegrini; Maria Giovanna Maturo; Claudia Martorelli; Mariano Suppa; Ambra Antonini; Dimitra Kostaki; Lucilla Verna; Maria Teresa Landi; Ketty Peris; Maria Concetta Fargnoli
Journal:  Melanoma Res       Date:  2017-06       Impact factor: 3.599

2.  Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.

Authors:  Nicholas J Taylor; Nancy E Thomas; Hoda Anton-Culver; Bruce K Armstrong; Colin B Begg; Klaus J Busam; Anne E Cust; Terence Dwyer; Lynn From; Richard P Gallagher; Stephen B Gruber; Diane E Nishri; Irene Orlow; Stefano Rosso; Alison J Venn; Roberto Zanetti; Marianne Berwick; Peter A Kanetsky
Journal:  Int J Cancer       Date:  2016-05-30       Impact factor: 7.396

3.  Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.

Authors:  Steven Vernali; Weston T Waxweiler; Patrick M Dillon; Peter A Kanetsky; Irene Orlow; Li Luo; Klaus J Busam; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; Anne E Cust; David W Ollila; Colin B Begg; Marianne Berwick; Nancy E Thomas
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

Review 4.  Germline mutations predisposing to melanoma.

Authors:  Atrin Toussi; Nicole Mans; Jeanna Welborn; Maija Kiuru
Journal:  J Cutan Pathol       Date:  2020-05-11       Impact factor: 1.587

5.  Phenotypic Characteristics and Melanoma Thickness in Women.

Authors:  Reza Ghiasvand; Adèle C Green; Torkjel M Sandanger; Elisabete Weiderpass; Trude E Robsahm; Marit B Veierød
Journal:  Acta Derm Venereol       Date:  2021-04-29       Impact factor: 3.875

6.  Relationship of Chromosome Arm 10q Variants to Occurrence of Multiple Primary Melanoma in the Population-Based Genes, Environment, and Melanoma (GEM) Study.

Authors:  Jonathan A Miles; Irene Orlow; Peter A Kanetsky; Li Luo; Anne E Cust; Bruce K Armstrong; Anne Kricker; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; David C Gibbs; Klaus J Busam; Vikram Mavinkurve; David W Ollila; Colin B Begg; Marianne Berwick; Nancy E Thomas
Journal:  J Invest Dermatol       Date:  2018-12-17       Impact factor: 7.590

7.  The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response.

Authors:  Rosamaria Pinto; Simona De Summa; Sabino Strippoli; Brunella Pilato; Amalia Azzariti; Gabriella Guida; Michele Guida; Stefania Tommasi
Journal:  Oncotarget       Date:  2016-05-03

8.  The complementary effect of rs1042522 in TP53 and rs1805007 in MC1R is associated with an elevated risk of cutaneous melanoma in Latvian population.

Authors:  Aija Ozola; Dace Ruklisa; Dace Pjanova
Journal:  Oncol Lett       Date:  2019-09-20       Impact factor: 2.967

9.  MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project.

Authors:  Saverio Caini; Sara Gandini; Francesca Botta; Elena Tagliabue; Sara Raimondi; Eduardo Nagore; Ines Zanna; Patrick Maisonneuve; Julia Newton-Bishop; David Polsky; DeAnn Lazovich; Rajiv Kumar; Peter A Kanetsky; Veronica Hoiom; Paola Ghiorzo; Maria Teresa Landi; Gloria Ribas; Chiara Menin; Alexander J Stratigos; Giuseppe Palmieri; Gabriella Guida; Jose Carlos García-Borrón; Hongmei Nan; Julian Little; Francesco Sera; Susana Puig; Maria Concetta Fargnoli
Journal:  Melanoma Res       Date:  2020-10       Impact factor: 3.199

10.  Functional Characterization of MC1R-TUBB3 Intergenic Splice Variants of the Human Melanocortin 1 Receptor.

Authors:  Cecilia Herraiz; Conchi Olivares; Maria Castejón-Griñán; Marta Abrisqueta; Celia Jiménez-Cervantes; José Carlos García-Borrón
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.